Peroxynitrite-modified collagen-II induces p38/ERK and NF-κB-dependent synthesis of prostaglandin E2 and nitric oxide in chondrogenically differentiated mesenchymal progenitor cells

Osteoarthritis and Cartilage

Volumn 14, Issue 5, 2006, Pages 460-470

  Whiteman, M ^a   Spencer, J P E ^a,b   Zhu, Y Z ^a   Armstrong, J S ^a   Schantz, J T ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Chondrocyte; Nitric oxide; Osteoarthritis; Peroxynitrite; Rheumatoid arthritis

Indexed keywords

COLLAGEN TYPE 2; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PEROXYNITRITE; PEROXYNITRITE MODIFIED COLLAGEN TYPE 2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; JOINT DEGENERATION; MESENCHYMAL STEM CELL; OSTEOARTHRITIS; PLASTIC SURGERY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS; TISSUE REPAIR; TRABECULAR BONE; UPREGULATION;

ARTHRITIS; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE II; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEMBRANE PROTEINS; MESENCHYMAL STEM CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEROXYNITROUS ACID; PHOSPHORYLATION;

EID: 33646131834     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2005.11.002     Document Type: Article

References (82)

1. Henrotin Y., Jurz B., and Aigner T. Oxygen and oxygen free radicals in cartilage degradation: friends or foes?. Osteoarthritis Cartilage 13 (2005) 643-645
2. Bauerova K., and Bezek A. Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen Physiol Biophys 18 (1999) 15-20
3. Jang D., and Murrell G.A. Nitric oxide in arthritis. Free Radic Biol Med 24 (1998) 1511-1519
4. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med 45 (2003) 7-13
5. Whal S.M., McCartney-Francis N., Chan J., Dionne R., Ta L., and Orenstein J.M. Nitric oxide in experimental joint inflammation. Benefit or detriment?. Cells Tissues Organs 174 (2003) 26-33
6. Studer R., Jaffurs D., Stefanovic-Racic M., Robbins P.D., and Evans C.H. Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 7 (1999) 377-379
7. Henrotin Y.E., Bruckner P., and Pujol J.P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 11 (2003) 747-755
8. Huie R.E., and Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 18 (1993) 195-199
9. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87 (1990) 1620-1624
10. Radi R. Peroxynitrite reactions and diffusion in biology. Chem Res Toxicol 11 (1998) 720-721
11. Murphy M.P., Packer M.A., Scarlett J.L., and Martin S.W. Peroxynitrite: a biologically significant oxidant. Gen Pharmacol 31 (1998) 179-186
12. Van der Vliet A., Smith D., O'Neill C.A., Kaur H., Darley-Usmar V., Cross C.E., et al. Interactions of peroxynitrite with human plasma and its constituents: oxidative damage and antioxidant depletion. Biochem J 303 (1994) 295-301
13. Ignarro L.J., Fukuto J.M., Griscavage J.M., Rogers N.E., and Byrns R.E. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from l-arginine. Proc Natl Acad Sci U S A 90 (1993) 8103-8110
14. Grabowski P.S., Wright P.K., Van't Hof R.J., Helfrich M.H., Ohshima H., and Ralston S.H. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 36 6 (1997 Jun) 651-655
15. Abramson S.B., Attur M., Amin A.R., and Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 3 (2001) 535-541
16. Pelletier J.P., Jovanovic D., Fernandes J.C., Manning P., Connor J.R., Currie M.G., et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 41 (1998) 1275-1286
17. Pelletier J.P., Lascau-Coman V., Jovanovic D., Fernandes J.C., Manning P., Connor J.R., et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 26 (1999) 2002-2014
18. Mabley J.J., Liaudet L., Pacher P., Southan G.J., Groves J.T., Salzman A.L., et al. Part II: beneficial effects of the peroxynitrite decomposition catalyst FP15 in murine models of arthritis and colitis. Mol Med 8 (2002) 581-590
19. Brahn E., Banquerigo M.L., Fierstein G.S., Boyle D.L., Salzman A.L., and Szabo C. Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. J Rheumatol 25 (1998) 1785-1793
20. Halliwell B., Zhao K., and Whiteman M. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good: a personal view of recent controversies. Free Radic Res 31 (1999) 651-659
21. Greenacer S.A.B., and Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 34 (2001) 514-581
22. Kaur H., and Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 350 (1994) 9-12
23. Matsuo M., Nishida K., Yoshida A., Murakami T., and Inoue H. Expression of caspase-3 and -9 relevant to cartilage destruction and chondrocyte apoptosis in human osteoarthritic cartilage. Acta Med Okayama 55 (2001) 333-340
24. Loeser R.F., Carlson C.S., Del Carlo M., and Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 46 (2002) 2349-2357
25. Sandhu J.K., Robertson S., Birnboim H.C., and Goldstein R. Distribution of protein nitrotyrosine in synovial tissues of patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 30 (2003) 1173-1181
26. Mapp P.I., Klocke R., Walsh D.A., Chana J.K., Stevens C.R., Gallagher P.J., et al. Localization of 3-nitrotyrosine to rheumatoid and normal synovium. Arthritis Rheum 44 (2001) 1534-1539
27. Whiteman M., Armstrong J.S., Cheung N.S., Siau J.L., Rose P., Schantz J.T., et al. Peroxynitrite mediates calcium-dependent mitochondrial dysfunction and cell death via activation of calpains. FASEB J 18 (2004) 1395-1397
28. Deberg M., Labasse A., Christgau S., Cloos P., Bang Henrickson D., Chapelle J.P., et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13 (2005) 258-265
29. Crofford L.J. COX-2 in synovial tissues. Osteoarthritis Cartilage 7 (1999) 406-408
30. Kojima F., Kato S., and Kawai S. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol 19 (2005) 255-261
31. Crofford L.J. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 24 Suppl 49 (1997) 15-19
32. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science 298 (2002) 1911-1912
33. Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 16 (2004) 616-622
34. Sweeney S.E., and Firestein G.S. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 16 (2004) 231-237
35. Amin A.R., Attyr M., and Abramson S.B. Nitric oxide synthase and cyclooxygenase: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 11 (1999) 202-209
36. Handel M.L., McMorrow L.B., and Gravallese E.M. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38 (1995) 1762-1770
37. Marok R., Winyard P.G., Coumbe A., Kus M.L., Gaffney K., Blades S., et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 39 (1996) 583-591
38. Han Z.N., Boyle D.L., Manning A.M., and Firestein G.S. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28 (1998) 197-208
39. Clancy R., Rediske J., Koehne C., Stoyanovsky D., Amin A., Attur M., et al. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Osteoarthritis Cartilage 9 (2001) 294-299
40. Mendes A.F., Caramona M.M., Carvalho A.P., and Lopes M.C. Role of mitogen-activated protein kinases and tyrosine kinases on IL-1-induced NF-kappaB activation and iNOS expression in bovine articular chondrocytes. Nitric Oxide 6 (2002) 35-44
41. Pelletier J.P., Fernandes J.C., Jovanovic D.V., Reboul P., and Martel-Pelletier J. Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. J Rheumatol 28 (2001) 2509-2519
42. Martel-Pelletier J., Mineau F., Jovanovic D., Di Battista J.A., and Pelletier J.P. Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis Rheum 42 (1999) 2399-2409
43. Wada Y., Nakajima-Yamada T., Yamada K., Tsuchida J., Yasumoto T., Shimozato T., et al. R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur J Pharmacol 506 (2005) 285-295
44. Westra J., Limburg P.C., de Boer P., and van Rijswijk M.H. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 63 (2004) 1453-1459
45. Nishikawa M., Myoui A., Tomita T., Takahi K., Nampei A., and Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 48 (2003) 2670-2681
46. English J.M., and Cobb M.H. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23 (2002) 40-45
47. Agarwal S., Deschner J., Long P., Verma A., Hofman C., Evans C.H., et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 50 (2004) 3541-3548
48. Blackwell N.M., Sembi P., Newson J.S., Lawrence T., Gilroy D.W., and Kabouridis P.S. Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor. Arthritis Rheum 50 (2004) 2675-2684
49. Cuzzocrea S., Chatterjee P.K., Mazzon E., Dugo L., Serraino I., Britti D., et al. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 135 (2002) 496-510
50. Guo X.M., Wang C.Y., Wang Y.H., Duan C.M., Zhao Q., and Sun D.M. Experimental study of the isolation, culture and in chondrogenic differentiation of human bone mesenchymal stem cell. Zhonghua Kou Qiang Yi Xue Za Zhi 38 (2003) 63-66
51. Alsalameh S., Amin R., Gemba T., and Lotz M. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. Arthritis Rheum 50 (2004) 1522-1532
52. Jones E.A., Kinsey S.E., English A., Jones R.A., Straszynski L., Meredith D.M., et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 46 (2002) 3349-3360
53. Yoo J.U., Barthel T.S., Nishimura K., Solchaga L., Caplan A.I., Goldberg V.M., et al. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am 80 (1998) 1745-1757
54. Endres M., Hutmacher D.W., Salgado A.J., Kaps C., Ringe J., Reis R.L., et al. Osteogenic induction of human bone marrow-derived mesenchymal progenitor cells in novel synthetic polymer-hydrogel matrices. Tissue Eng 9 (2003) 689-702
55. Beckman J.S., Chen J., Ischiopoulos H., and Crow J.P. Oxidative chemistry of peroxynitrite. Methods Enzymol 233 (1994) 229-240
56. Hughes M.N., and Nicklin H.G. The chemistry of pernitrites. Part I. Kinetics and decomposition of pernitrous acid. J Chem Soc A (1968) 450-452
57. Olszowski S., Mak P., Olszowska E., and Marcinkiewicz J. Collagen type II modification by hypochlorite. Acta Biochim Pol 5 (2003) 471-479
58. Davies J.M., Horwitz D.A., and Davies K.J. Potential roles of hypochlorous acid and N-chloroamines in collagen breakdown by phagocytic cells in synovitis. Free Radic Biol Med 15 (1993) 637-643
59. Ischiropoulos H., and al-Mehdi A.B. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 364 (1995) 279-282
60. Whiteman M., Armstrong J.S., Chu S.H., Jia-Ling S., Wong B.S., Cheung N.S., et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'?. J Neurochem 90 (2004) 765-768
61. Whiteman M., Siau J.L., and Halliwell B. Lack of tyrosine nitration by hypochlorous acid in the presence of physiological concentrations of nitrite. Implications for the role of nitryl chloride in tyrosine nitration in vivo. J Biol Chem 278 (2003) 8380-8384
62. Buss H., Chan T.P., Sluis K.B., Domigan N.M., and Winterbourn C.C. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 23 (1997) 631-666
63. Rose P., Won Y.K., Ong C.-N., and Whiteman M. Inhibition of lipopolysaccharide-induced iNOS and COX-II expression and activity via NF-κB degradation by dietary isothiocyanates. Nitric Oxide 12 (2005) 237-243
64. Babu B.R., and Griffith O.W. Design of isoform-selective inhibitors of nitric oxide synthase. Curr Opin Chem Biol 2 (1998) 491-500
65. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Iizuka H., et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24 (1993) 105-110
66. Kelemen B.R., Hsiao K., and Goueli S.A. Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 277 (2002) 8741-8748
67. Laufer S.A., Wagner G.K., Kotschenreuther D.A., and Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem 46 (2003) 3230-3244
68. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98 (2001) 13681-13686
69. Whiteman M., Rose P., Siau J.L., and Halliwell B. Nitrite-mediated protection against hypochlorous acid-induced chondrocyte toxicity: a novel cytoprotective role of nitric oxide in the inflamed joint?. Arthritis Rheum 48 (2003) 3140-3150
70. Dobashi K., Asayama K., and Shirahata A. Differential effects of cyclic AMP on induction of nitric oxide synthase in 3T3-L1 cells and brown adipocytes. Free Radic Biol Med 35 (2003) 94-101
71. Yu S.M., Wu J.F., Lin T.L., and Kuo S.C. Inhibition of nitric oxide synthase expression by PPM-18, a novel anti-inflammatory agent, in vitro and in vivo. Biochem J 328 (1997) 363-369
72. Davis M.E., Grumbach I.M., Fukai T., Cutchins A., and Harrison D.G. Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding. J Biol Chem 279 (2004) 163-168
73. 3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-κB and reactive oxygen species. J Cell Biochem 95 (2005) 955-969
74. Eiserich J.P., Estevez A.G., Bamberg T.V., Ye Y.Z., Chumley P.H., Beckman J.S., et al. Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury. Proc Natl Acad Sci U S A 96 (1999) 6365-6370
75. Whiteman M., and Halliwell B. Loss of 3-nitrotyrosine on exposure to hypochlorous acid: implications for the use of 3-nitrotyrosine as a bio-marker in vivo. Biochem Biophys Res Commun 258 (1999) 168-172
76. Kanadia R.N., and Shanbhag V.P. Denitration of peroxynitrite-treated proteins by "protein nitratases" from dog prostate. Biochem Mol Biol Int 47 (1999) 1061-1070
77. Pargellis C., and Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Invest Drugs 4 (2003) 566-571
78. Saccani S., Pantano S., and Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3 (2002) 69-75
79. Thomas B., Thirion S., Humbert L., Tan L., Goldring M.B., Bereziat G., et al. Differentiation regulates interleukin-1beta-induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase. Biochem J 362 (2002) 367-373
80. Badger A.M., Cook M.N., Lark M.W., Newman-Tarr T.M., Swift B.A., Nelson A.H., et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 161 (1998) 467-473
81. Badger A.M., Roshak A.K., Cook M.N., Newman-Tarr T.M., Swift B.A., Carlson K., et al. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage 8 (2000) 434-443
82. Foster M.L., Halley F., and Souness J.E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect 13 (2000) 488-497